Triple therapy aims to wipe out rectal tumors before surgery
NCT ID NCT07297030
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This phase 2 trial tests a new approach for people with high-risk locally advanced rectal cancer. Participants will receive a short course of radiation with a boost to the tumor, combined with chemotherapy (capecitabine and oxaliplatin) and an immunotherapy drug (tislelizumab). The goal is to see if this combination can make the tumor disappear completely before any surgery, potentially improving long-term outcomes. The study plans to enroll 37 adults aged 18 to 75.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Short-course radiotherapy with simultaneous integrated boost, capecitabine, oxaliplatin, and tislelizumab (a PD-1 inhibitor)
What this could lead to
If successful, this could offer a more effective neoadjuvant treatment for high-risk rectal cancer, potentially increasing the chance of complete tumor disappearance before surgery.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. The combination of radiation, chemotherapy, and immunotherapy may cause severe side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.